

Cash Merger

November 17, 2021

Exchange/Memo ID:205288

ONN / OCC ID: 49598



Trillium Therapeutics Inc. - Cash Settlement/Acceleration of Expirations

DESCRIPTION:

On October 26, 2021, Shareholders of Trillium Therapeutics Inc. (TRIL) voted concerning the proposed Arrangement Agreement with PF Argentum Acquisition ULC, a wholly-owned subsidiary of Pfizer Inc. The arrangement was approved and subsequently consummated before the open on November 17, 2021. As a result, each existing TRIL Common Share will be converted into the right to receive \$18.50 net cash per share.

Pending Contract Adjustments:

Pursuant to the By-Laws of the Options Clearing Corporation ("OCC"), the below options will be adjusted as follows.

Adjustment Date:	November 17, 2021
Option Symbol:	TRIL remains TRIL
Underlying Security:	TRIL remains TRIL
Contract Multiplier:	1
Strike Divisor:	1
New Multiplier:	100
New Deliverable:	\$1,850.00 Cash (\$18.50 x 100)

Pricing Considerations:

Additional Exchange Info: Any resting orders in the above options in the BOX order book will cancelled by the BOX Market Operations Center after the close today November 17th, 2021.

Disclaimer: This Information Memo summarizes corporate events affecting listed options. No warranty of accuracy or completeness is given with respect to the summary. Option series information is based on series existing at OCC at the time this Memo was generated.

Contact Information: Questions regarding this memo can be addressed to the BOX Market Operations Center at 617-235-2291 or toll free at 1-866-768-8845 or emailed to boxmoc@boxoptions.com.

